{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-336780","form_type":"8-K","ticker":"AGEN","cik":"0001098972","company_name":"AGENUS INC","filed_at":"2026-08-06T11:52:23+00:00","discovered_at":"2026-08-06T11:55:01.388039+00:00","generated_at":"2026-08-06T11:55:07.598377+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Agenus Q2 revenue $34.5M; $85M placement funds Phase 3 ROBBIN trial in MSS colon cancer","bullets":["Q2 total revenue $34.5M (up from $25.7M YoY); pre-commercial product revenue $6.4M.","Completed $85M private placement in July; warrants could add up to $255M.","Phase 3 ROBBIN trial of BOT+BAL in neoadjuvant MSS colon cancer to start Q1 2027; targets 38,000 US patients annually.","Discontinued funding for BATTMAN Phase 3 study (CCTG sponsored) to prioritize ROBBIN.","Near-term milestones: NEST/UNICORN manuscripts H2 2026; corporate webcast Sept 10."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-336780","json":"https://secwatch.observer/filing/0001193125-26-336780.json","markdown":"https://secwatch.observer/filing/0001193125-26-336780.md","text":"https://secwatch.observer/filing/0001193125-26-336780.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1098972/000119312526336780/0001193125-26-336780-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1098972/000119312526336780/agen-20260806.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-06T11:55:07.598377+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}